Genome-Wide Association Study Identifies Genetic Loci for Antibody Response to SARS-CoV-2 Vaccines in Patients With Systemic Autoimmune Diseases and Healthy Individuals
Authors' conclusion
This study highlights both MHC and non-MHC genetic contributions to SARS-CoV-2 vaccine responses and suggests these effects are consistent across patients with SADs and healthy individuals
Study context
- Population
- Patients with systemic autoimmune diseases and healthy individuals, all of whom received nucleic acid-based SARS-CoV-2 vaccines
- Participants
- 165 patients
- Comparison
- Patients with systemic autoimmune diseases vs healthy individuals
- Systemic autoimmune diseases (SADs)n = 138
- Healthy controlsn = 27reference
- Outcome
- Postvaccination anti-SARS-CoV-2 IgG antibody levels (spike protein receptor-binding domain (RBD) and nucleocapsid)
- Follow-up
- Between 1 and 12 months after vaccination
Methodological detailsmeta-analysis with a previously published genome-wide association study (GWAS) of 1076 healthy individuals
- Meta-analysis with a previously published GWAS of 1076 healthy individuals
Pooled result
As reported in the abstract
Genetic loci associated with postvaccination anti-SARS-CoV-2 IgG levels (meta-analysis)
Novel association near RACGAP1 (rs706785), βmeta
−0.30
Novel association near RACGAP1 (rs706785), P meta
3.85 × 10-8
Replicated association at HLA-DRB1 position 71, βmeta
−0.23
Replicated association at HLA-DRB1 position 71, P meta
1.94 × 10-11
Further pooled results
- No significant interactions between genotype and disease status
Original publication
Genome-Wide Association Study Identifies Genetic Loci for Antibody Response to SARS-CoV-2 Vaccines in Patients With Systemic Autoimmune Diseases and Healthy Individuals. J Rheumatol. Published 1 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →